{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:38:19Z","timestamp":1784115499132,"version":"3.55.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Australian National Health and Medical Research Council (NHMRC","award":["APP1121151"],"award-info":[{"award-number":["APP1121151"]}]},{"name":"NHMRC Investigator","award":["GNT1173346"],"award-info":[{"award-number":["GNT1173346"]}]},{"name":"NHMRC Investigator","award":["APP1185416"],"award-info":[{"award-number":["APP1185416"]}]},{"name":"Australian Government Research Training Program scholarship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There are few readily modifiable risk factors for epithelial ovarian cancer; preclinical studies suggest bisphosphonates could have chemopreventive actions. Our study aimed to assess the association between use of nitrogen-based bisphosphonate medicine and risk of epithelial ovarian cancer, overall and by histotype.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a case-control study nested within a large, linked administrative dataset including all Australian women enrolled for Medicare, Australia\u2019s universal health insurance scheme, between July 2002 and December 2013. We included all women with epithelial ovarian cancer diagnosed at age 50\u2009years and older between July 1, 2004, and December 31, 2013 (n\u2009=\u20099367) and randomly selected up to 5 controls per case, individually matched to cases by age, state of residence, area-level socioeconomic status, and remoteness of residence category (n\u2009=\u200946\u200a830). We used prescription records to ascertain use of nitrogen-based bisphosphonates (ever use and duration of use), raloxifene, and other osteoporosis medicines (no nitrogen-based bisphosphonates, strontium and denosumab). We calculated adjusted odds ratios (OR) and 95% confidence intervals (CI) using conditional logistic regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ever use of nitrogen-based bisphosphonates was associated with a reduced risk of epithelial ovarian cancer compared with no use (OR\u2009=\u20090.81, 95% CI = 0.75 to 0.88). There was a reduced risk of endometrioid (OR\u2009=\u20090.51, 95% CI = 0.33 to 0.79) and serous histotypes (OR\u2009=\u20090.84, 95% CI = 0.75 to 0.93) but no association with the mucinous or clear cell histotypes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Use of nitrogen-based bisphosphonates was associated with a reduced risk of endometrioid and serous ovarian cancer. This suggests the potential for use for prevention, although validation of our findings is required.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djac050","type":"journal-article","created":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T12:17:35Z","timestamp":1646655455000},"page":"878-884","source":"Crossref","is-referenced-by-count":14,"title":["Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older"],"prefix":"10.1093","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5944-5085","authenticated-orcid":false,"given":"Karen M","family":"Tuesley","sequence":"first","affiliation":[{"name":"School of Public Health, Faculty of Medicine, University of Queensland , Brisbane, Australia"},{"name":"Population Health Department, QIMR Berghofer Medical Research Institute , Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0733-5930","authenticated-orcid":false,"given":"Penelope M","family":"Webb","sequence":"additional","affiliation":[{"name":"School of Public Health, Faculty of Medicine, University of Queensland , Brisbane, Australia"},{"name":"Population Health Department, QIMR Berghofer Medical Research Institute , Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6452-7571","authenticated-orcid":false,"given":"Melinda M","family":"Protani","sequence":"additional","affiliation":[{"name":"School\u2002 of Public Health, Faculty of Medicine, University of Queensland , Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7434-2957","authenticated-orcid":false,"given":"Katrina","family":"Spilsbury","sequence":"additional","affiliation":[{"name":"Institute for Health Research, The University of Notre Dame Australia , Fremantle, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7137-6855","authenticated-orcid":false,"given":"Sallie-Anne","family":"Pearson","sequence":"additional","affiliation":[{"name":"Centre for Big Data Research in Health, The University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7019-7502","authenticated-orcid":false,"given":"Michael D","family":"Coory","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne , Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7934-601X","authenticated-orcid":false,"given":"Peter","family":"Donovan","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Royal Brisbane and Women\u2019s Hospital , Brisbane, Australia"},{"name":"Faculty of Medicine, University of Queensland , Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7677-3339","authenticated-orcid":false,"given":"Christopher","family":"Steer","sequence":"additional","affiliation":[{"name":"Border Medical Oncology, Albury-Wodonga Regional Cancer Centre , Albury, Australia"},{"name":"University of NSW Rural Clinical School, Albury Campus , Albury, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2015-6320","authenticated-orcid":false,"given":"Louise M","family":"Stewart","sequence":"additional","affiliation":[{"name":"School of Population and Global Health, The University of Western Australia , Perth, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-4968","authenticated-orcid":false,"given":"Nirmala","family":"Pandeya","sequence":"additional","affiliation":[{"name":"School of Public Health, Faculty of Medicine, University of Queensland , Brisbane, \u2002Australia"},{"name":"Population Health Department, QIMR Berghofer Medical Research Institute , Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4566-1414","authenticated-orcid":false,"given":"Susan J","family":"Jordan","sequence":"additional","affiliation":[{"name":"School of Public Health, Faculty of Medicine\u2002, University of Queensland , Brisbane, Australia"},{"name":"Population\u2002 Health Department, QIMR Berghofer Medical Research Institute , Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"2022061408193468700_djac050-B1","author":"Ferlay"},{"issue":"5","key":"2022061408193468700_djac050-B2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/1753-6405.12471","article-title":"Cancers in Australia in 2010 attributable to modifiable factors: summary and conclusions","volume":"39","author":"Whiteman","year":"2015","journal-title":"Aust N Z J Public Health"},{"issue":"19","key":"2022061408193468700_djac050-B3","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2174\/1568026616666160216154946","article-title":"Repurposing drugs for cancer prevention","volume":"16","author":"Lee","year":"2016","journal-title":"Curr Top Med Chem"},{"issue":"12","key":"2022061408193468700_djac050-B4","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1016\/S1470-2045(20)30610-0","article-title":"Drug repurposing in oncology","volume":"21","author":"Frantzi","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"2022061408193468700_djac050-B5","doi-asserted-by":"publisher","first-page":"E331","DOI":"10.15167\/2421-4248\/jpmh2020.61.3.1497","article-title":"Do statins play any role in reducing the incidence and mortality of ovarian cancer? A systematic review and meta-analysis","volume":"61","author":"Mohammadian-Hafshejani","year":"2020","journal-title":"J Prev Med Hyg"},{"issue":"6","key":"2022061408193468700_djac050-B6","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1002\/ijc.33311","article-title":"Aspirin and the risk of nondigestive tract cancers: an updated meta-analysis to 2019","volume":"148","author":"Santucci","year":"2021","journal-title":"Int J Cancer"},{"issue":"5","key":"2022061408193468700_djac050-B7","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11914-020-00612-4","article-title":"Benefits of bisphosphonate therapy: beyond the skeleton","volume":"18","author":"Billington","year":"2020","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"2022061408193468700_djac050-B8","doi-asserted-by":"publisher","first-page":"8090","DOI":"10.1038\/s41598-017-08649-9","article-title":"Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells","volume":"7","author":"Abdullah","year":"2017","journal-title":"Sci Rep"},{"issue":"42","key":"2022061408193468700_djac050-B9","doi-asserted-by":"publisher","first-page":"72147","DOI":"10.18632\/oncotarget.20046","article-title":"Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer","volume":"8","author":"Kobayashi","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"2022061408193468700_djac050-B10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ygyno.2018.06.012","article-title":"Risk reduction of endometrial and ovarian cancer after bisphosphonates use: a meta-analysis","volume":"150","author":"Zhang","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"24","key":"2022061408193468700_djac050-B11","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1200\/JCO.2016.66.8178","article-title":"Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium","volume":"34","author":"Wentzensen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2022061408193468700_djac050-B12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ygyno.2016.11.019","article-title":"Worldwide comparison of ovarian cancer survival: histological group and stage at diagnosis (CONCORD-2)","volume":"144","author":"Matz","year":"2017","journal-title":"Gynecol Oncol"},{"key":"2022061408193468700_djac050-B13","year":"2013"},{"key":"2022061408193468700_djac050-B14"},{"key":"2022061408193468700_djac050-B15","volume-title":"Addressing Locational Disadvantage Effectively (International Evidence)","author":"Ware","year":"2010"},{"key":"2022061408193468700_djac050-B16"},{"issue":"8","key":"2022061408193468700_djac050-B17","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.clinthera.2019.05.001","article-title":"Real-world adherence and persistence with bisphosphonate therapy in postmenopausal women: a systematic review","volume":"41","author":"Fardellone","year":"2019","journal-title":"Clin Ther"},{"issue":"3","key":"2022061408193468700_djac050-B18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2147\/cia.s2046","article-title":"Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women","volume":"3","author":"Lambrinoudaki","year":"2008","journal-title":"Clin Interv Aging"},{"issue":"6","key":"2022061408193468700_djac050-B19","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/ije\/dyw341","article-title":"Robust causal inference using directed acyclic graphs: the R package \u2018dagitty\u2019","volume":"45","author":"Textor","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"2","key":"2022061408193468700_djac050-B20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jclinepi.2010.02.015","article-title":"Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting","volume":"64","author":"Lu","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2022061408193468700_djac050-B21","doi-asserted-by":"publisher","first-page":"e021122","DOI":"10.1136\/bmjopen-2017-021122","article-title":"The validity of the Rx-Risk Comorbidity Index using medicines mapped to the Anatomical Therapeutic Chemical (ATC) Classification System","volume":"8","author":"Pratt","year":"2018","journal-title":"BMJ Open"},{"issue":"1","key":"2022061408193468700_djac050-B22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/pds.5367","article-title":"Predicting obesity and smoking using medication data: A machine-learning approach","volume":"31","author":"Ali","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2022061408193468700_djac050-B23","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1093\/ije\/dyu149","article-title":"Good practices for quantitative bias analysis","volume":"43","author":"Lash","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"2","key":"2022061408193468700_djac050-B24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1530\/ERC-12-0395","article-title":"Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium","volume":"20","author":"Olsen","year":"2013","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2022061408193468700_djac050-B25","doi-asserted-by":"publisher","first-page":"e1000181","DOI":"10.1371\/journal.pmed.1000181","article-title":"Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis","volume":"6","author":"Banks","year":"2009","journal-title":"PLoS Med"},{"issue":"4","key":"2022061408193468700_djac050-B26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the e-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"529","key":"2022061408193468700_djac050-B27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/01621459.2018.1529598","article-title":"Sensitivity analysis for unmeasured confounding in meta-analyses","volume":"115","author":"Mathur","year":"2020","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"2022061408193468700_djac050-B28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women","volume":"35","author":"Reid","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2022061408193468700_djac050-B29","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/bjc.2013.383","article-title":"Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case-control studies using two primary-care databases","volume":"109","author":"Vinogradova","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"2022061408193468700_djac050-B30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2004.04.024","article-title":"Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen","volume":"220","author":"Song","year":"2005","journal-title":"Cancer Lett"},{"issue":"2","key":"2022061408193468700_djac050-B31","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1006\/gyno.2001.6578","article-title":"The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women","volume":"85","author":"Neven","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"9574","key":"2022061408193468700_djac050-B32","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","article-title":"Ovarian cancer and hormone replacement therapy in the Million Women Study","volume":"369","author":"Beral","year":"2007","journal-title":"Lancet"},{"key":"2022061408193468700_djac050-B33","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ajog.2005.08.047","article-title":"Epidemiology, etiology, and diagnosis of osteoporosis","volume":"194(suppl 2","author":"Lane","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"2022061408193468700_djac050-B34","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1517\/14656566.2011.557360","article-title":"Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene","volume":"12","author":"Ko","year":"2011","journal-title":"Expert Opin Pharmacother"},{"issue":"1-2","key":"2022061408193468700_djac050-B35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.mce.2004.02.020","article-title":"Estrogen and progesterone receptors in ovarian epithelial tumors","volume":"221","author":"Lindgren","year":"2004","journal-title":"Mol Cell Endocrinol"},{"issue":"9980","key":"2022061408193468700_djac050-B36","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(14)61687-1","article-title":"Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies","volume":"385","author":"Gapstur","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"2022061408193468700_djac050-B37","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1089\/jwh.2008.1341","article-title":"Bone fractures and incident epithelial ovarian cancer in a prospective cohort study","volume":"18","author":"Danforth","year":"2009","journal-title":"J Womens Health (Larchmt))"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djac050\/43297898\/djac050.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/114\/6\/878\/44035563\/djac050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/114\/6\/878\/44035563\/djac050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T08:19:57Z","timestamp":1655194797000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/114\/6\/878\/6545294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,9]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3,9]]},"published-print":{"date-parts":[[2022,6,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djac050","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,3,9]]}}}